Fig. 1: The effect of i.v. iron on the composite endpoint of total (first and recurrent) HF hospitalizations and cardiovascular mortality for the first 12 months of follow-up (PB = 0.007, I2 = 47%). | Nature Medicine

Fig. 1: The effect of i.v. iron on the composite endpoint of total (first and recurrent) HF hospitalizations and cardiovascular mortality for the first 12 months of follow-up (PB = 0.007, I2 = 47%).

From: Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency

Fig. 1

The Forest plot illustrates the impact of i.v. iron on the composite endpoint of total (first and recurrent) HF hospitalizations and cardiovascular mortality during the first 12 months of follow-up using a Bayesian random-effects meta-analysis. Data are presented as RRs with 95% CIs. Sensitivity analyses were conducted by omitting the FAIR-HF and CONFIRM-HF studies, through the application of alternative HN priors and using the Knapp–Hartung (KnHa) approach to random-effects meta-analysis. n or N, no. of events or no. of participants in the group, respectively. The blue color indicates analysis using six trials and the red color analysis using four trials.

Back to article page